Primecap Management Co. CA Sells 1,000 Shares of Prothena Co. plc (NASDAQ:PRTA)

Primecap Management Co. CA trimmed its holdings in shares of Prothena Co. plc (NASDAQ:PRTA) by 2.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,500 shares of the biotechnology company’s stock after selling 1,000 shares during the quarter. Primecap Management Co. CA’s holdings in Prothena were worth $594,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Signaturefd LLC grew its stake in Prothena by 182.1% in the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 863 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Prothena by 13.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock valued at $211,000 after buying an additional 1,186 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Prothena by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock worth $173,000 after buying an additional 4,026 shares during the last quarter. ProShare Advisors LLC raised its position in Prothena by 8.9% in the first quarter. ProShare Advisors LLC now owns 11,346 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 932 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Prothena in the third quarter valued at about $210,000. 97.08% of the stock is currently owned by institutional investors.

Prothena Stock Up 1.1 %

PRTA stock opened at $14.60 on Friday. Prothena Co. plc has a twelve month low of $13.22 and a twelve month high of $41.54. The firm has a market capitalization of $785.63 million, a PE ratio of -5.81 and a beta of 0.16. The stock has a 50-day simple moving average of $17.66 and a two-hundred day simple moving average of $20.12.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $1.22 million. During the same quarter in the previous year, the company earned $0.38 earnings per share. Prothena’s revenue for the quarter was down 98.9% on a year-over-year basis. On average, equities research analysts anticipate that Prothena Co. plc will post -2.25 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PRTA shares. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research note on Monday, September 30th. StockNews.com lowered Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $84.00 price target on shares of Prothena in a research note on Wednesday, November 13th. Oppenheimer decreased their price objective on Prothena from $66.00 to $62.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Finally, Royal Bank of Canada dropped their price objective on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $61.86.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.